Use of preferentially replicating bacteria for the treatment of cancer

被引：135

作者：

Sznol, M ^{[1
]}

Lin, SL ^{[1
]}

Bermudes, D ^{[1
]}

Zheng, LM ^{[1
]}

King, I ^{[1
]}

机构：

[1] Vion Pharmaceut Inc, New Haven, CT 06511 USA

来源：

关键词：

D O I：

10.1172/JCI9818

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

[No abstract available]

引用

页码：1027 / 1030

页数：4

共 19 条

[1] CAREY R. W., 1967, EUR J CANCER, V3, P37, DOI 10.1016/0014-2964(67)90060-6
[2] Regulation of the proinflammatory effects of Fas ligand (CD95L)
Chen, JJ
Sun, YN
Nabel, GJ
[J]. SCIENCE, 1998, 282 (5394) : 1714 - 1717
[3] Clairmont C., 1999, CLIN CANC RES S, V5, P102
[4] ENGELBART K, 1964, CANCER RES, V24, P239
[5] Fox ME, 1996, GENE THER, V3, P173
[6] Fox ME, 1996, GENE THER, V3, P741
[7] Type III secretion machines:: Bacterial devices for protein delivery into host cells
Galán, JE
Collmer, A
[J]. SCIENCE, 1999, 284 (5418) : 1322 - 1328
[8] The Salmonella dublin virulence plasmid does not modulate early T-Cell responses in mice
Guilloteau, LA
Lax, AJ
MacIntyre, S
Wallis, TS
[J]. INFECTION AND IMMUNITY, 1996, 64 (01) : 222 - 229
[9] HEMODYNAMIC AND TRANSPORT BARRIERS TO THE TREATMENT OF SOLID TUMORS
JAIN, RK
[J]. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1991, 60 (1-2) : 85 - 100
[10] Kops S. K., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P7